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In this study, we attempted to identify the molecular determinants in the genome of the attenuated Sabin 2 vaccine strain
of poliovirus that may change during vaccine production and result in an increase in monkey neurovirulence. An extensive
search for suitable vaccine lots identified six batches that had failed the monkey neurovirulence test (MNVT). On repeated
tests, these batches were found to have acceptable levels of monkey neurovirulence. One of the batches was additionally
passaged six times under conditions used in vaccine production, and the resulting high-passage sample was screened for
the presence of mutations and tested in monkeys. In addition to the previously described A3 G reversion at nucleotide 481,
high-passage stock also contained a mutation in the VP1-coding region (3364 5 G3 A) that consistently accumulated in the
course of passaging. However, despite the presence of substantial amounts of these mutations, high-passage stock passed
the MNVT. Replication of Sabin 2 poliovirus in the central nervous system of transgenic mice susceptible to poliovirus or in
cultures of mouse cells, resulted in another mutation (3363 5 A 3 G). Even though its presence correlated with paralysis
in mice, the introduction of 3363-G into the Sabin 2 genome did not increase neurovirulence of the virus. Previous studies
identified the 481-G mutation as an important determinant of monkey neurovirulence. We prepared virus samples with varying
amounts of genetically defined single mutants at this nucleotide and tested them in monkeys. The results demonstrated that
even a 100% substitution at this site introduced into Sabin 2 strain did not increase monkey neurovirulence. The determi-
nation of the nucleotide sequence of an alternative strain used for the production of type 2 OPV (Chung 2) showed that it
contained 100% of the wild-type 481-G but possessed an extremely low level of neurovirulence. These results demonstrate
the remarkable stability of the attenuated phenotype of the Sabin 2 strain and show that (1) no batch of OPV 2 has ever
repeatedly failed the MNVT, (2) growing the virus beyond the passage level allowed in vaccine production did not result in
increased neurovirulence in monkeys, (3) a test for neurovirulence in transgenic mice may be more sensitive than the MNVT,
and (4) determination of the mutational profile of vaccine batches detects inconsistencies in vaccine manufacturing
processing that would not be detected by the MNVT. © 1999 Academic Press
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fINTRODUCTION
Oral poliovirus vaccine (OPV), which is made from live
ttenuated Sabin strains of poliovirus (Sabin, 1955), is
ne of the most successful vaccines ever used. During
lmost 40 years, billions of children were immunized,
esulting in almost complete eradication of the disease.
owever, its inherent genetic instability has caused con-
erns about the consistency of vaccine production, de-
anding rigorous testing of each manufactured lot of the
accine (WHO, 1990). This includes the monkey neuro-
irulence test (MNVT), which requires intraspinal inocu-
ation of hundreds of monkeys a year in the United States
lone. Type 3 OPV is known to be the most unstable of
he three poliovirus types, with failures of commercial
accine batches in the MNVT not uncommon in the early
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152ays of vaccine production. Nucleotide sequence anal-
sis of attenuated and revertant strains has identified
olecular determinants of neurovirulence in both the
oding region and the 59-untranslated region (Minor et
l., 1993). We developed a sensitive and quantitative
ethod to detect revertants in batches of OPV and
howed that neurovirulent revertants are present in ev-
ry commercial batch of type 3 OPV (Chumakov et al.,
991). The quantity of these revertants determines
hether a batch of type 3 OPV passes or fails the MNVT
nd can be used to assess the acceptability of vaccine
atches (Chumakov et al., 1993, 1992). Thus determining
he mutational profiles of vaccine batches can be used to
onitor the consistency of OPV production.
For type 1 and type 2 OPV, the situation is more
omplicated; during almost 40 years of OPV production,
o batch of these strains has consistently failed the
NVT. In the case of type 1, a few batches originally
ailed the MNVT, but all were shown later, in repeated
ests, to have low levels of neurovirulence. Recently, we
ound that the extensive passaging of type 1 OPV in cell
ulture resulted in accumulation of the specific muta-
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153GENETIC STABILITY OF TYPE 2 OPVions in the 59-UTR (480-A and 525-C) (Rezapkin et al.,
994). However, even a 6-fold excess of these mutants
ver the levels found in regular vaccine batches led to no
easurable increase in neurovirulence for monkeys
Rezapkin et al., 1998). The extraordinary stability of the
ttenuated phenotype suggests that the consistency of
PV 1 production may be better monitored by molecular
ethods than by the MNVT.
In the case of type 2, there also has been no confirmed
eport of any commercial vaccine batch that consistently
ailed the MNVT. Our extensive search for such “failed”
ots identified four batches that did not initially pass the
NVT, but retesting, they all were found to be accept-
ble. Recently, two additional lots that failed the initial
NVT were produced, and we took this opportunity to
xamine their molecular profiles in an attempt to identify
olecular determinants that could be used to monitor
he consistency of type 2 OPV. In addition, we looked at
he quantitative effects of a mutation at nucleotide 481 of
he 59-UTR by preparing mixtures of genetically engi-
eered single-point mutant strains. We also studied the
ucleotide sequence and neurovirulence of an alterna-
ive strain of type 2 poliovirus used to produce OPV in
hina (Chung 2). Here we report findings that suggest
he attenuated phenotype of Sabin 2 strain of poliovirus
s extremely stable and that the mutation at nucleotide
81 contributes very little, if anything, to monkey neuro-
irulence. We conclude that as with OPV 1, the consis-
ency of OPV 2 production can be better monitored by
tudying the mutational profile of the product using quan-
itative molecular techniques.
RESULTS AND DISCUSSION
In a previous study, we found that the Sabin 2 strain
as genetically stable under conditions used for vaccine
anufacturing but that neurovirulence increased slightly
hen the virus was grown under exotic conditions, such
s serial propagation in excess of five passages at
levated temperatures (37°C) (Taffs et al., 1995). We
dentified and quantified a number of mutations, includ-
ng 481-G, that were present in these high-passage sam-
les. Because the mutations were present in a mixture,
e were unable to identify those that played a critical
ole in increased neurovirulence. To do so, we would
ave had to create genetically defined samples with
ingle mutants and test them in monkeys. Even this
pproach might have failed, however, because in many,
f not all, cases, neurovirulence is determined by more
han one mutation. In addition, stocks with increased
eurovirulence described in our previous report (Taffs et
l., 1995) were derived through propagation under ex-
reme conditions, and the findings were not particularly
elevant to the actual manufacturing process. Therefore,
o evaluate the usefulness of molecular mutational anal-
sis of vaccine batches (MAPREC) for monitoring the ponsistency of OPV 2 production, we sought real batches
f OPV 2 that had failed the MNVT. At that time, we failed
o identify any such batches. Four vaccine lots produced
y foreign manufacturers and provided by Dr. David
ood (NIBSC, UK) had reportedly failed an initial MNVT.
e tested these batches by MAPREC and found that
one contained an excess of 481-G revertants. We also
epeated the MNVT and found that all of the suspect
atches had acceptable levels of neurovirulence for rhe-
us monkeys (data not shown).
Recently, one manufacturer produced two batches of
PV 2 that failed a MNVT conducted according to the
HO protocol, and we obtained these batches for our
tudies. We refer to them as batches C and D. We
ompared the C and D batches with two older batches,
and B, produced by the same manufacturer that had
assed the MNVT.
MAPREC analyses of batches A–D showed that even
hough the failed C and D batches contained slightly
ore 481-G than did batches A and B, the difference was
nsignificant, and the absolute content of 481-G in the C
nd D lots did not exceed that in the US national neuro-
irulence reference vaccine NB-2 (Table 1). Therefore,
e decided to look for other mutations that might be
resent in these lots. To do so, we used a previously
escribed strategy (Taffs et al., 1995) and passaged the
atches under conditions similar to those used for vac-
ine production, thereby allowing mutations to accumu-
ate beyond a detectable level. Batch D was serially
assaged by the manufacturer six times (D 1 6). Results
f sequence heterogeneity analysis (Rezapkin et al.,
994) showed that in addition to a rapidly accumulating
81-A3 G mutation, only three other mutations could be
dentified: 869-C 3 U changing Ala41 to Val in VP4,
173-C3 U changing Ala231 to Val in VP1, and 3364-G3
changing Glu295 to Lys in VP1. MAPREC analyses of
accine stocks showed that of these three mutations,
nly 3364-G 3 A could be found in trace amounts in
ome vaccine batches. On passaging in cell culture, this
utation, identified in our previous study (Taffs et al.,
995), rapidly accumulated.
We also used another approach to identify mutations
hat might be linked to increased neurovirulence. Polio-
irus inoculation of Tg-PVR21 transgenic mice that ex-
TABLE 1
Mutant Content in Batches of OPV 2
Sample 481-G 3363-G 3364-A
B-2 reference 1.050% 0.069% 0.005%
ot A 0.670% 0.145% 0.074%
ot B 0.450% 0.066% 0.014%
ot C 0.720% 0.252% 0.132%
ot D 1.040% 0.273% 0.150%ress the human poliovirus receptor (CD 155) results in
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154 REZAPKIN ET AL.linical poliomyelitis in some mice, depending on the
ose. Tg-PVR21 mice were inoculated intraspinally with
ype 2 OPV, and virus was reisolated from their spinal
ords. Two of the isolates were completely sequenced,
nd the mutations found are listed in Table 2. In addition
o the well known reversion at nucleotide 481, there was
mutation in the gene coding for VP1 capsid protein in
oth isolates (3363-A 3 G). The results of partial se-
uencing and MAPREC analysis of many of other iso-
ates, both from healthy and paralyzed mice, are pre-
ented in Fig. 1. As shown, paralysis of mice was strongly
ssociated with the presence of 481-G, whereas roughly
alf of the isolates from paralyzed mice also contained
363-G. Only two isolates from healthy mice contained
363-G. The correlation between mutations and paraly-
is was not absolute, however, because some isolates
rom healthy mice contained both mutations and some
solates from paralyzed mice contained neither. There
ere trace amounts of 3363-G mutants in all vaccine
atches (Table 1). It is noteworthy that all three mutations
hat we tested (481-G, 3363-G, and 3364-A) were present
n higher amounts in lots C and D than in lots A and B,
uggesting that the virus may have undergone more
xtensive replication during manufacture.
The 3363-A 3 G mutation is immediately adjacent to
he 3364-G3 A mutation, described above, that consis-
ently accumulates in Sabin 2 virus grown in cell culture.
owever, unlike 3364-G 3 A, which changes glutamic
cid to lysine at amino acid 295 of VP1, 3363-A 3 G is
ilent and cannot have been selected because of
hanges in viral capsid structure. This unexpected ob-
ervation prompted us to study the possible role of this
utation. Because 3363-A3 G was isolated from mice,
e wondered whether the same mutation would accu-
ulate in mouse cells in vitro. Therefore, we passaged
abin 2 virus in L20B cells (mouse L cells expressing
TABLE 2
Mutations Found in Sabin 2 Isolates from
the Spinal Cord of Transgenic Mice
Nucleotide Gene Amino acid
Sabin
nucleotide
Isolatesa
1 2
156 59-NTR U C
190 59-NTR G A
481 59-NTR A G G
961 VP2 Asn-Asp 3 A G
2547 VP1 Silent U C
2908 VP1 Ile-Val 143 A G
3363 VP1 Silent A G G
5067 2C Silent C U
5220 3A Silent U C
6910 3D Silent C U
a Only nucleotides distinguishing isolates from the Sabin strain are
thown.uman CD155) and in Vero cells (derived from African
reen monkey kidneys). Figure 2 shows that, indeed,
363-A 3 G was selected in mouse cells in vitro, but
hen passaging was continued in monkey cells, it grad-
ally disappeared. In contrast, 3364-G3 A accumulated
n the monkey cells but disappeared in the mouse cells
Fig. 2D). Such reciprocal behavior, as well as the close
roximity of these mutations, suggests that the mecha-
isms of their selection and deselection may be linked,
ut details remain a mystery. Besides 3364-G 3 A, we
ound that 3365-A 3 C also accumulated when D 1 6
irus stock was further passaged in Vero cells (data not
hown).
The alternative attenuated Chung 2 strain of type 2
oliovirus (see below) contains a 3365-A 3 G mutation.
n previous studies, we found that another silent muta-
ion, 3369-G 3 A, occurred consistently when Sabin 2
as grown in Vero cells (Taffs et al., 1995). Therefore, it
ppears that a small region coding for the C-terminus of
P1 is genetically unstable in the Sabin 2 virus (Fig. 3).
The involvement of a junction between the P1 and P2
rimary polyprotein cleavage products in the species
pecificity of poliovirus has been noticed before. Some
s-yet-unidentified role for the VP1-2A region in species-
pecific virulence determinants was described for the
ouse-adapted type 1 polio strain Mahoney LSa (Lu et
l., 1994). A mouse-neurovirulent (mn) phenotype of Ma-
oney LSa was attributed to mutations in the C-terminus
f the VP1 and in the N-terminus of 2A; those mutations
anifested themselves only in concert and were ineffec-
ual when present alone. In addition, the mn mutations in
he nonstructural protein 2A also affected the thermosta-
ility of the virions, prompting the authors to suggest that
FIG. 1. Contents of 481-G and 3363-G mutants in Sabin 2 poliovirus
tocks isolated from spinal cords of transgenic mice. F, M, Contents of
he two mutations in viral isolates from paralyzed and healthy mice,
espectively, except for strains with 0% or 100% (see symbols at the
orners of the figure), where symbols were positioned arbitrarily to
how the number of isolates of a particular genotype.he 2A-coding region of type 1 poliovirus RNA may spe-
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155GENETIC STABILITY OF TYPE 2 OPVifically interact with VP1 to stabilize the virions. The
ituation described in this report resembles that found
or mouse-adapted Mahoney LSa (Lu et al., 1994). In both
ases, propagation in mouse cells resulted in an accu-
ulation of mutations in the same region, and one of the
utations affected the same amino acid in both types of
FIG. 2. Selection of 481-G, 3363-G, and 3364-A in cell cultures of
ouse and monkey origin. (A–C) Sabin 2 strain was passaged three
imes in mouse L20B cells, and then passaging was continued either in
20B cells (f) or in Vero (continuous monkey kidney) cells (E). (D)
esults of passaging in mouse L20B cells of a Sabin 2 stock (D 1 6,
ee text) that had accumulated 481-G and 3364-A mutations during its
revious growth for six passages in primary embryonal monkey kidney
ells.oliovirus (Thr1433 Ala in type 1 and Ile1433 Val in type v). The silent nature of two of the mutations described in
his report also points to a possible involvement of RNA–
rotein interactions. The location of these mutations on
he boundary of the P1 and P2 products of a primary
olyprotein cleavage hints at their possible involvement
n the modulation of this process by facilitating the
roper spatial arrangement of the nascent polypeptide
hain, perhaps along with some species-specific host
actors.
The preferential accumulation of 3363-A 3 G in the
entral nervous system of transgenic mice, as well as
nalogies with the mn determinants of Mahoney LSa
irus (Lu et al., 1994), suggested that this mutation might
e involved in mouse neurovirulence. To study this pos-
ibility, we created a site-directed mutant with 3363-G in
conventional Sabin 2 context and tested it for neuro-
irulence in Tg-PVR21 mice. This intraspinal test for
ouse neurovirulence, developed in our laboratory, has
een shown to discriminate between acceptable and
nacceptable batches of type 3 OPV (Dragunsky et al.,
993, 1996). Table 3 shows that there was no increase in
eurovirulence, at least when the 3363-G mutation was
resent alone, suggesting that it may merely adapt Sabin
virus to grow better in rodent cells without affecting its
bility to infect neuronal cells specifically. On the other
and, mutations in this region may not only adapt polio-
irus to replication in mouse cells but also play some
ole in attenuation because both Sabin 2 and Chung 2
accine strains have mutations in this region and the
assaging of Sabin 2 in primate cells results in an ac-
umulation of 3364-G 3 A mutations.
To investigate the role of 3364-G 3 A and other mu-
ations, we engineered a special viral construct that
ontained all the mutations found to accumulate in D 1
, except 481-G, which was reported to increase neuro-
irulence. To do this, we used the recently developed
pproach of “quasispecies engineering,” which amplifies
ull-length cDNA of poliovirus by PCR (Chumakov, 1996).
nlike conventional cDNA plasmid-based engineering,
he new approach preserves the entire mutational diver-
ity of a natural viral population and allows it to be
anipulated. Figure 4 shows the derivation scheme of
he construct. Table 3 presents the results of a Tg-PVR21
ransgenic mouse test and demonstrates that the muta-
ions that accumulated in D 1 6 did not, by themselves,
ncrease viral neurovirulence.
Failure of lots C and D in the initial MNVT correlates
ith increased contents of all mutations that we quanti-
ied in these lots. It is clear, however, that the MNVT was
ot sufficiently discriminating to unambiguously classify
hese lots as unacceptable. In contrast, the neuroviru-
ence test in transgenic mice was more sensitive; lots C
nd D consistently paralyzed more mice on intraspinal
noculation than did equal doses of the WHO neuroviru-
ence reference, and thus they failed the MNVT. Of two
accine lots that passed the MNVT, one lot failed the
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156 REZAPKIN ET AL.ouse test (A), whereas another passed (B); it is of
nterest that lot B had the lowest mutant content of all
our lots (see Table 1).
Most of the above reasoning is based on the previ-
usly published assertion that type 2 OPV samples with
levated levels of 481-G have increased neurovirulence.
ata supporting this assertion were derived from several
ines of indirect evidence (Pollard et al., 1989). We de-
ided to check this assumption directly; we tested the
1 6 stock (tissue culture passage 6 of commercial lot
, previously reported to be a failed batch of type 2 OPV)
s well as the original vaccine batch. To our surprise,
oth stocks passed the MNVT performed according to
HO recommendations (Table 4). There were only mar-
inal increases in the histological lesion scores, which
ere statistically insignificant. Therefore, these results
how that a batch of virus derived from a putatively
eurovirulent source and further passaged six times be-
ond the level used in vaccine and containing dramati-
ally increased amounts of several mutations still had
cceptable neurovirulence. Together with results of the
g-mouse test performed with quasispecies-engineered,
igh-passage stock from which the 481-G mutation was
subtracted” (Table 3), these results show that no muta-
ion that accumulated in Sabin 2 virus after six passages
ncreased viral neurovirulence. Besides demonstrating
FIG. 3. Mutations at the
T
Neurovirulence Test in Intraspinall
Virus sample Description 481-
WHO/II NV reference 0.35
QP-27049 D 1 6 minus 481-Ga 0.30
QP-27050 Construct with 3363-G 0.58a Passage 6 with 481-G “subtracted” by quasispecies engineering.he impressive genetic stability of the attenuation phe-
otype of the Sabin 2 strain, these results illustrate the
uperiority of MAPREC for monitoring the consistency of
PV production.
Other important information obtained from this study
oncerns the possible role of the 481-G reversion, gen-
rally thought to be an important determinant of neuro-
irulence. This reversion is located in the same domain
f the 59-UTR of type 2 OPV, as is the demonstrably
eurovirulent 472-C reversion in type 3 poliovirus. Be-
ause 481-G consistently accumulates during virus
rowth both in vitro and in vivo, it was imperative to study
ts quantitative effects on the neurovirulence of type 2
irus. The experiment described above showed that a
igh-passage stock containing 20% 481-G did not have
ncreased neurovirulence. It might be argued, however,
hat other mutations suppressed the effect of 481-G. To
tudy the role of this mutation alone, we prepared two
enetically engineered constructs, one of which had the
onventional sequence of the Sabin 2 strain, whereas
he other differed by a single base change at nucleotide
81. Sequencing of the plasmid with cDNA of type 2
oliovirus, provided by Dr. A. Macadam (NIBSC), re-
ealed three base substitutions that distinguished the
DNA copy from the consensus sequence of the Sabin 2
train. We corrected this plasmid using site-directed mu-
VP1 coding sequence.
lated Tg-PVR21 Transgenic Mice
Contents of mutants
No. of mice
Paralyzed/Total3363-G 3364-A
0.01% 0.05% 14/30 (47%)
0.00% 22.7% 15/30 (50%)
52.0% 0.04% 8/30 (27%)ABLE 3
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157GENETIC STABILITY OF TYPE 2 OPVagenesis and rederived live viral stocks from it. Then we
repared mixtures of 481-A and 481-G viruses and tested
hem in monkeys. In the first monkey test, we tested
tocks containing up to 6% 481-G, a level that is about 10
imes higher than that found in commercial vaccine
atches. In the next MNVT, we tested a stock with 100%
81-G; its level of neurovirulence was also low (Table 5).
herefore, we concluded that when present alone, 481-G
oes not increase the neurovirulence of type 2 poliovirus
or monkeys.
Other evidence that 481-G plays no significant role in
FIG. 4. Scheme of “mutant subtraction” by PCR-based quasispecies
ngineering (Chumakov, 1996). cDNA (dashed line) made from viral
NA containing point mutations and sequence heterogeneities (shown
s F, n, , and X) is PCR-amplified to make full-length DNA (step 1A),
nd then a mutagenized 59-segment containing T7 RNA-polymerase
romoter is introduced (step 1B). Next, these PCR products are recom-
ined in vitro (step 2) to produce a full-length DNA containing all the
riginal sequence heterogeneities except for the mutation that was
subtracted” from the mutational profile of the original viral quasispe-
ies. (Open circle denotes the “subtracted” mutation, replaced by an-
ther nucleotide.)
TABLE 4
Monkey Neurovirulence Tests of a Production Batch of OPV 2
nd a Derivative Batch Prepared by Six Passages in Monkey
idney Cells
Sample Lesion score
Lot D 0.65 6 0.51
Lot D 1 6 passages 0.73 6 0.31
Reference 0.61 6 0.47fonkey neurovirulence came from our studies with
hung 2, an alternative strain of type 2 poliovirus used
or OPV production in China. The strain was derived by
erial passaging at low multiplicity and low temperature.
e sequenced Chung 2 completely and found that it
iffers from the Sabin 2 strain at 52 sites (Table 6). Most
mportantly, we found that it has a wild-type G at nucle-
tide 481. The strain elicited exceptionally low histolog-
cal lesion scores in rhesus monkeys (0.15 6 0.09 vs
.68 6 0.35 for the US reference).
In this report, we have shown that the growth of Sabin
ype 2 poliovirus is accompanied by an accumulation of
utations in the 59-UTR as well as at the end of the P1
oding region. The mechanism of selection for some of
hese mutants remains obscure, but clearly the muta-
ions do not increase the neurovirulence of the virus. In
ontrast to previously published studies (Pollard et al.,
989), based on neurovirulence tests performed with as
ew as four monkeys, we demonstrated that the Sabin 2
train with a single revertant mutation to G at nucleotide
81 did not have increased neurovirulence when tested
n a WHO MNVT, that is, in 12 monkeys compared with a
eference vaccine tested concurrently in an equal num-
er of animals. This unexpected finding falls in line with
growing body of evidence demonstrating that muta-
ions in the 59-noncoding region of type 1 and type 2
olioviruses (unlike the case of type 3) do not play an
mportant role in attenuation/neurovirulence as once
hought. Findings supporting this notion for type 1 polio-
irus were recently published by our group (Rezapkin et
l., 1998) as well as by others (McGoldrick et al., 1995).
Even though 481-G plays no direct role in neuroviru-
ence, it can serve as a useful marker for the consistency
f vaccine production because it readily and consistently
ccumulates in OPV prepared by serial passaging under
onditions of vaccine production. Contents of 481-G dif-
er in vaccines made by different manufacturers (Taffs et
l., 1995). Thus unlike the case of type 3 OPV, where
here is a clear and consistent threshold of revertant
ontent above which vaccine batches are likely to fail the
NVT (about 1.0% 472-C), for type 2 OPV each manufac-
urer should determine the consistent levels of revertants
haracteristic of their vaccines and monitor new batches
TABLE 5
Monkey Neurovirulence Test of Sabin 2 Stocks
with Varying Contents of 481-G
Sample Lesion score
0.2% 481-G 0.24 6 0.11
0.8% 481-G 0.10 6 0.06
5.8% 481-G 0.23 6 0.22
100% 481-G 0.46 6 0.17
Reference 0.38 6 0.18or conformity with the previously established profile.
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158 REZAPKIN ET AL.ome other mutations might also be used for this pur-
ose (e.g. 3364-A), but their contents in batches of OPV
are extremely low and their accurate quantification is
ifficult.
The pragmatic goal of our studies was to determine
hether the MNVT monitoring of OPV 2 production can
e replaced by MAPREC. The absence of type 2 OPV
atches that were found unacceptable by the MNVT
uring almost 40 years of OPV history, as well as our
ailed attempts to prepare experimental samples with
ncreased neurovirulence for monkeys, even though the
amples contained substantial amounts of a number of
utations, casts doubt on the justification for the contin-
TABLE 6
Nucleotide Sequence of Chung 2 Attenuated
Strain of Type 2 Poliovirus
Nucleotide Gene Amino acid Sabin 2 Chung 2
49 59-NTR U C
156 59-NTR U C
169 59-NTR U C
402 59-NTR A G
481 59-NTR A G
663 59-NTR U C
707 59-NTR A G
810 VP4 Silent C U
1014 VP2 Silent U C
1038 VP2 Silent G A
1530 VP2 Silent U C
1997 VP3 His-Arg 77 A G
2520 VP1 Silent U C
2682 VP1 Silent C U
2909 VP1 Ile-Thr 143 T C
3042 VP1 Silent U C
3365 VP1 Glu-Gly 295 A G
3510 2A Silent U C
3609 2A Silent C U
4710 2C Silent U A
4740 2C Silent A G
4944 2C Silent A G
5006 2C Lys-Arg 295 A G
5034 2C Ile-Thr 303 U C
5313 3A Silent U C
5364 3A Silent G A
5430 3B Silent A G
5523 3C Silent A G
5579 3C Ala-Val 48 C U
5787 3C Silent U C
5788 3C Ala-Thr 118 G A
6079 3D Tyr-His 32 U C
6095 3D Val-Ala 37 U C
6193 3D Val-Met 70 G A
6281 3D Asp-Gly 99 A G
6402 3D Silent G A
6435 3D Silent U C
7092 3D Silent G A
7095 3D Silent U C
7131 3D Silent G A
7338 3D Silent U Ced use of the MNVT to monitor type 2 OPV. Unlike the bituation with type 3 OPV, where the MNVT has clearly
emonstrated its usefulness in detecting substandard
ots of vaccine, for type 1 (Rezapkin et al., 1998) and type
vaccines, the ability of the MNVT to detect unaccept-
ble vaccine lots has never been demonstrated unam-
iguously. We have found that experimental batches of
ype 2 OPV prepared under grossly inappropriate condi-
ions (six passages beyond the level acceptable for pre-
aring vaccine) had dramatically increased contents of
everal mutations, but they were still judged to be ac-
eptable by the MNVT.
This leads us to the crucial concern about the rela-
ionship among the results of the MNVT and of the
APREC and the safety of OPV for humans. For decades,
controversy about the cause of vaccine-associated
aralytic poliomyelitis (VAPP) could not be resolved. Two
lausible explanations have been proposed: (1) revertant
accine virus as a causative agent of these very rare
ases, or (2) some still-unidentified factors in vaccine
ecipients or in their environment that predispose some
ersons to develop clinical poliomyleitis when infected
y strains that would be harmless to most other individ-
als. The first explanation was favored in early studies of
he VAPP phenomenon when revertant virus with in-
reased monkey neurovirulence was isolated from vic-
ims of VAPP. However, a fundamental difficulty in ac-
epting this explanation derives from the fact that the
ajority of healthy vaccine recipients also excrete rever-
ants with similar levels of neurovirulence. Support for
he second explanation comes from studies performed in
ountries with substantially increased rates of VAPP. A
igher incidence was observed despite the fact that the
accine used did not cause any excess of VAPP in other
ountries, suggesting that it was not related to vaccine
uality (Strebel et al., 1994). Ability to cause extremely
are cases of VAPP may be an intrinsic property of Sabin
trains. Wild-type polioviruses cause paralytic disease in
nly 1 of 100 to 1000 infected individuals, and factors
etermining the outcome of infection are not clear. At-
enuated strains of poliovirus possess much lower levels
f pathogenicity (which are not zero, however, but are
oughly 1 in 1 million), a tolerable situation by risk–
enefit analysis during the time when chances of wild-
ype poliovirus infection were substantial. Recently, we
erformed a retrospective analysis to investigate
hether OPV batches linked to VAPP during a period of
ore than 20 years could be discriminated from those
ot related to VAPP by available laboratory methods. The
esults, to be published elsewhere (J. Beeler et al., manu-
cript in preparation), showed that neither MNVT nor
APREC was predictive of the disease in humans. In
ther words, all cases of VAPP were caused by vaccine
atches indistinguishable by any available test method
rom batches that did not cause VAPP. Therefore, in full
ccord with the opinion often expressed by Dr. Sabin, we
elieve that MNVT and MAPREC, for this matter, are
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159GENETIC STABILITY OF TYPE 2 OPVtrictly consistency tests. The role of both methods in
afety control of vaccine is to ensure the manufacture of
standardized product with a well-established safety
ecord.
Results presented in this report suggest that molecu-
ar methods of mutational analysis may be superior for
he identification of substandard lots of vaccine. Data
resented here and to be published elsewhere show that
ransgenic mice may be more sensitive to some muta-
ions than are monkeys and that the MNVT may comple-
ent MAPREC in monitoring the consistency of OPV
roduction.
MATERIALS AND METHODS
irus growth
The virus was passaged in primary cultures of cyno-
olgus monkey embryonal kidney cells under conditions
sed for vaccine production. Two sets, six consecutive
assages each, were prepared: one at an input multi-
licity of 1.0 TCID50/cell and the other at 0.1 TCID50/cell.
ome passaging was also done in continuous Vero cells
African green monkey kidney, passage level 138–150)
nd in mouse L20B cells expressing the CD 155 human
oliovirus receptor (passage level 20–25). Vaccine
atches made from the Chung 2 strain were kindly pro-
ided by Dr. Guo Ren (Institute of Medical Biology, Chi-
ese Academy of Medical Science, Beijing, China).
equencing and mutant quantification
Sequences were determined by PCR cycle-sequenc-
ng (GIBCO BRL) of PCR-amplified full-length viral
DNAs. Special attention was given to the identification
f sequence heterogeneities (Rezapkin et al., 1994). Each
uspected heterogeneity was independently confirmed
y mutant analysis with PCR and restriction enzyme
leavage (MAPREC) (Chumakov et al., 1991). Procedures
or RNA isolation, cDNA synthesis, PCR, and MAPREC
ave been described elsewhere (Chumakov et al., 1993,
991; Lu et al., 1993; Taffs et al., 1995).
uasispecies engineering
The preparation of genetically altered viral stocks was
erformed by PCR mutagenesis and in vitro PCR recom-
ination of full-length viral cDNA copies (Chumakov,
996). Live virus was recovered from HEp-2c cells trans-
ected with RNA transcribed in vitro by T7 RNA polymer-
se from full-length PCR-amplified DNA. Unlike conven-
ional engineering using recombinant plasmids, this
CR-based technique allows preservation and manipu-
ation of an entire heterogeneous population of viral
enetic variants.
reparing poliovirus stock from cDNA plasmid
Poliovirus stocks with lowest possible sequence het-
rogeneity were derived from cloned cDNA. The Sabin 2 tlasmid was kindly provided by Dr. Andrew Macadam
NIBSC); in our previous study (Taffs et al., 1995), it was
ound to contain three mutations distinguishing it from
he Sabin 2 consensus sequence (1014 U3 C, 2547 U3
, and 6647 U 3 C). Therefore, the sequence was
orrected by site-directed mutagenesis. Four segments
f poliovirus DNA were amplified using respective mu-
agenic primers, and the full-length DNA was assembled
rom these fragments by ligase chain reaction. An in vitro
NA transcript of this DNA was transfected into HEp-2c
ells, and live viruses were recovered. Two virus stocks
ere prepared: one containing 481-A and the other con-
aining 481-G. They were mixed in the desired propor-
ions and tested in monkeys.
onkey neurovirulence test
Tests were performed according to WHO recommen-
ations (1990). Twelve juvenile rhesus monkeys were
noculated in the lumbar region of the spinal cord with 0.1
l of Sabin 2 poliovirus (6.0–6.5 log10 TCID50/monkey).
istological examination of the central nervous system
as performed after 17 days of clinical observations; the
everity of lesions was scored and compared with that in
group of monkeys inoculated with a reference vaccine.
eurovirulence test in Tg-PVR21 transgenic mice
Transgenic mice expressing human poliovirus recep-
or (CD155) (Koike, 1991) were bred and provided by Dr.
. Nomura, (Central Institute of Experimental Animals,
awasaki, Japan). The mice were inoculated intraspinally
nd observed for 14 days for clinical signs of poliomy-
litis (Abe et al., 1995; Dragunsky et al., 1996). Clinical
igns were scored and compared with those in a group
f mice inoculated with a reference vaccine. Even though
he neurovirulence test in transgenic mice may occa-
ionally produce results differing from those in monkeys,
t was shown that there is a very good correlation be-
ween the methods (Levenbook, 1997). Unlike inoculation
f nontransgenic mice, which produces disease distinct
rom poliomyelitis (Gromeier et al., 1995), the test in
g-PVR21 mice is a more adequate measure of neuro-
irulence potential of poliovirus. All procedures with lab-
ratory animals were performed under general anesthe-
ia as specified in protocols approved by the Institutional
nimal Care and Use Committee, CBER.
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